ストックスクリーナーアプリを入手
538.84
1.11%
5.90
前日終値:
$532.94
開ける：
$534.84
24時間の取引高:
973.80K
Relative Volume:
2.22
時価総額：
$26.84B
収益：
$3.17B
当期純損益:
$1.29B
株価収益率:
19.89
EPS:
27.0947
ネットキャッシュフロー:
$1.01B
1週間 パフォーマンス:
+4.08%
1か月 パフォーマンス:
-4.41%
6か月 パフォーマンス:
+11.02%
1年 パフォーマンス:
+79.96%
1日の値動き範囲:
$524.58
$541.03
1週間の範囲:
$490.80
$541.03
52週間の値動き範囲:
$292.34
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
名前
United Therapeutics Corp
セクター
電話
(301) 608-9292
住所
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, HLN, TEVA, ZTS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
538.84 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
17.45 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.03 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.36 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
72.66 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Raymond James | Outperform |
| 2025-10-20 | 開始されました | Wells Fargo | Underweight |
| 2025-09-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | アップグレード | Goldman | Sell → Neutral |
| 2024-02-05 | 開始されました | Leerink Partners | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2022-12-06 | 開始されました | UBS | Buy |
| 2022-12-05 | 開始されました | Goldman | Sell |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-20 | 繰り返されました | BofA Securities | Underperform |
| 2022-09-19 | 再開されました | Wedbush | Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Neutral |
| 2021-07-14 | アップグレード | Argus | Hold → Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-01 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-06-25 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-03-10 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-27 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-01-31 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 開始されました | BofA/Merrill | Underperform |
| 2019-08-01 | アップグレード | Jefferies | Underperform → Hold |
| 2019-08-01 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | アップグレード | UBS | Sell → Neutral |
| 2019-05-09 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | アップグレード | Standpoint Research | Hold → Buy |
| 2018-08-08 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 繰り返されました | Barclays | Underweight |
| 2018-01-18 | 再開されました | Credit Suisse | Underperform |
| 2017-12-27 | 繰り返されました | Wedbush | Outperform |
| 2017-04-27 | 繰り返されました | Wedbush | Outperform |
| 2017-03-30 | 開始されました | UBS | Sell |
| 2017-03-16 | 開始されました | Credit Suisse | Underperform |
すべてを表示
United Therapeutics Corp (UTHR) 最新ニュース
United Therapeutics Corp (UTHR) Valuation: PE, PB & Fair Value Analysis - TradingKey
United Therapeutics CEO Rothblatt sells $5 million in shares - Investing.com
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
Form 4 United Therapeutics Corporation For: 27 July By Investing.com - Investing.com Canada
United Therapeutics CEO Rothblatt sells $5.05 million in stock - Investing.com
United Therapeutics (UTHR) CEO sells 9,500 shares after option exercise - Stock Titan
United Therapeutics Corporation (UTHR) Stock Analysis: A Healthier Future with 25.5% Potential Upside - DirectorsTalk Interviews
United Therapeutics Corp (UTHR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
UTHR|United Therapeutics Corp|Price:528.470|Chg%:-1.060 - TradingKey
United Therapeutics Corp (NASDAQ: UTHR) CEO trades 9,500 shares in 10b5-1 plan - Stock Titan
United Therapeutics Corp. (UTHR) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Form 4 United Therapeutics Corporation For: 24 July By Investing.com - Investing.com South Africa
United Therapeutics Corp. (UTHR) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
United Therapeutics Director Christopher Patusky Awarded Stock Options and Common Shares in Annual Equity Grant - Kalkine Media
United Therapeutics Director Christopher Causey Awarded Stock Options and Common Shares in Annual Equity Compensation - Kalkine Media
United Therapeutics Director Louis Sullivan Updates Stock Holdings and Receives Annual Stock Option Grant - Kalkine Media
United Therapeutics Corp. (UTHR) Earnings Dates, Call Summary & Reports - TipRanks
Form 4 United Therapeutics Corporation For: 23 July By Investing.com - Investing.com South Africa
Form 4 United Therapeutics Corporation For: 23 July - Investing.com India
United Therapeutics CEO Rothblatt sells $5 million in shares By Investing.com - Investing.com Canada
United Therapeutics Corporation (UTHR) Stock Price, News, Quote & History - Yahoo! Finance Canada
United Therapeutics (UTHR) grants director Victor Dzau RSUs and stock options - Stock Titan
United Therapeutics (UTHR) director Victor Dzau submits initial Form 3 - Stock Titan
United Therapeutics (UTHR) awards RSUs and stock options to director - Stock Titan
United Therapeutics Corp (UTHR) awards RSUs and options to director - Stock Titan
United Therapeutics (UTHR) awards director 760 restricted stock units - Stock Titan
United Therapeutics (UTHR) awards 760 RSUs to board director Judy D. Olian - Stock Titan
United Therapeutics (UTHR) director gets RSU and stock option grants - Stock Titan
United Therapeutics (UTHR) awards RSUs and stock options to director Nilda Mesa - Stock Titan
United Therapeutics (UTHR) grants director 2,380 stock options at $527.07 - Stock Titan
United Therapeutics (UTHR) awards 2,380 stock options to director Causey - Stock Titan
United Therapeutics (UTHR) awards 2,380 stock options to board director - Stock Titan
United Therapeutics (UTHR) awards 760 RSUs in annual director grant - Stock Titan
United Therapeutics (NASDAQ: UTHR) grants stock units and options to director Kurzweil - Stock Titan
United Therapeutics Corp (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
United Therapeutics Boosts Board to 13 Members with Appointment of Esteemed Medical Expert Victor Dzau, M.D. - Kalkine Media
United Therapeutics (NASDAQ: UTHR) appoints Victor Dzau to board - Stock Titan
After 12 years as NAM president, Victor Dzau joins United Therapeutics board - Stock Titan
United Therapeutics Corp. (UTH) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
United Therapeutics to report Q2 2026 results on August 5 - scanx.trade
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026 - Yahoo Finance
ETFs Investing in United Therapeutics Corporation Stocks - TradingView
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
Form 4 United Therapeutics Corporation For: 21 July By Investing.com - Investing.com South Africa
United Therapeutics CEO Rothblatt sells $5.05m in stock By Investing.com - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $5.05m in stock - Investing.com
United Therapeutics (UTHR) CEO executes 9,500-share option exercise and sale - Stock Titan
Boehringer Alleges United Therapeutics Poached Staff, Secrets - Law360
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
Lobbying Update: $80,000 of UNITED THERAPEUTICS CORPORATION lobbying was just disclosed - Quiver Quantitative
United Therapeutics Corp (UTHR) - MSN
United Therapeutics Corp (UTHR) 財務データ
収益
当期純利益
現金流量
EPS
United Therapeutics Corp (UTHR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Aug 06 '26 |
Sale |
525.36 |
9,500 |
4,990,873 |
324,443 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Aug 06 '26 |
Option Exercise |
146.03 |
8,300 |
1,212,049 |
53,472 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Aug 06 '26 |
Sale |
517.05 |
8,300 |
4,291,512 |
45,172 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Aug 05 '26 |
Option Exercise |
135.42 |
9,500 |
1,286,490 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Aug 05 '26 |
Sale |
518.74 |
9,500 |
4,927,985 |
324,443 |
5.97%
0.86%
大文字化:
|
ボリューム (24 時間):